Amedisys (NASDAQ:AMED) Given Outperform Rating at Royal Bank of Canada

Amedisys (NASDAQ:AMED)‘s stock had its “outperform” rating reissued by stock analysts at Royal Bank of Canada in a report issued on Wednesday,Benzinga reports. They presently have a $100.00 target price on the health services provider’s stock. Royal Bank of Canada’s target price points to a potential upside of 8.96% from the company’s current price.

Separately, Stephens restated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amedisys currently has a consensus rating of “Hold” and an average price target of $100.75.

Amedisys Stock Up 0.2 %

Amedisys stock traded up $0.20 on Wednesday, hitting $91.78. 9,706 shares of the stock traded hands, compared to its average volume of 399,470. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95. The firm has a market cap of $3.01 billion, a P/E ratio of 36.42, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The business’s fifty day simple moving average is $92.17 and its 200 day simple moving average is $91.98.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million for the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. As a group, sell-side analysts forecast that Amedisys will post 4.4 earnings per share for the current year.

Institutional Investors Weigh In On Amedisys

Several institutional investors and hedge funds have recently made changes to their positions in AMED. MassMutual Private Wealth & Trust FSB lifted its position in Amedisys by 56.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 120 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock worth $32,000 after purchasing an additional 141 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 124 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Amedisys by 100.0% during the first quarter. UMB Bank n.a. now owns 386 shares of the health services provider’s stock valued at $36,000 after buying an additional 193 shares during the last quarter. Finally, HBW Advisory Services LLC bought a new stake in Amedisys in the 4th quarter worth about $38,000. Institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.